tbuckley/cabot-search huggingface dataset:
Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma
Authors: Bogdana Suchorska, Armin Giese, Annamaria Biczok, Marcus Unterrainer, Michael Weller, Mark Drexler, Peter Bartenstein, Ulrich Schüller, Jörg-Christian Tonn, Nathalie L Albert
Journal: Neuro-Oncology (2017)

Stratification of glioma according to isocitrate dehydrogenase 1/2 (IDH1/2) mutation and 1p/19q codeletion status has gained major importance in the new World Health Organization (WHO) classification. Parameters derived from uptake dynamics of 18F-fluoro-ethyl-tyrosine PET (18F-FET-PET) such as minimal time-to-peak (TTPmin) allow discrimination between different prognostic glioma subgroups, too. The present study is aimed at exploring whether TTPmin analysis provides prognostic information beyond the WHO classification. Three hundred patients with newly diagnosed WHO 2007 grades II–IV gliomas with 18F-FET-PET imaging at diagnosis were grouped into 4 subgroups (IDH1/2 mut–1p/19q codel; IDH1/2 mut–1p/19q non-codel; IDH1/2 wildtype WHO grade II and III tumors; and glioblastoma). Clinical and imaging factors such as age, Karnofsky performance score, treatment, TTPmin, and maximal tumor-to-brain ratio (TBRmax) were analyzed with regard to progression-free and overall survival (PFS and OS) via univariate and multivariate regression analysis. PFS and OS were longest in the IDH1/2 mut–1p/19q codel subgroup, followed by IDH1/2 mut–1p/19q non-codel, IDH1/2 wildtype, and GBM (P < 0.001). Further, outcome stratified by TTPmin with a cutoff of 17.5 minutes revealed significantly longer PFS and OS in patients with TTPmin >17.5 minutes (P < 0.001 for PFS and OS). Lower TBRmax values or the absence of 18F-FET uptake was also associated with favorable outcome in the entire group. In the subgroup analyses, longer median TTPmin was associated with improved outcome specifically in the IDH1/2 mut–1p/19q non-codel group. 18F-FET-PET–derived dynamic analysis defines prognostically distinct subgroups of IDH1/2 mutant–1p/19q non-codel gliomas which cannot be distinguished as yet by molecular marker analysis.
Myopic Choroidal Neovascularization
Authors: Chui Ming Gemmy Cheung, Jennifer J. Arnold, Frank G. Holz, Kyu Hyung Park, Timothy Y.Y. Lai, Michael Larsen, Paul Mitchell, Kyoko Ohno-Matsui, Shih-Jen Chen, Sebastian Wolf, Tien Yin Wong
Journal: Ophthalmology (2017)
微量アルブミン尿症を伴う管理されていない早朝高血圧における腎臓の交感神経の過剰作動の役割:日本早朝昇圧‐1(JMS‐1)研究
Authors: Kario Kazuomi, Matsui Yoshio, Shibasaki Seiichi, Eguchi Kazuo, Ishikawa Joji, Hoshide Satoshi, Ishikawa Shizukiyo, Kabutoya Tomoyuki, Shimada Kazuyuki
Journal: Circulation (2008)
Abstract 301: A Novel Tram Stent Method in Treatment of Coronary Bifurcation Lesions
Authors: Mark C Arokiaraj
Journal: Circulation Research (2015)

Aims: A novel coronary stent was designed for the treatment of coronary bifurcation lesion, and it was investigated for its performance by finite element analysis. Methods and Results: A coronary bifurcation model was created with the proximal vessel of 3.2 mm diameter, and the distal vessel after the side branch (2.3 mm) was 2.7 mm. A novel stent was designed with connections that had a profile of a tram. Laser cutting and shape setting of the stent was performed, and thereafter the stent was deployed over a balloon. The contact pressure, stresses on the artery wall, stresses on the stent, the maximal principal log strain of the main artery and the side-branch were studied. The finite element study was performed in Abaqus, Simulia.The stresses on the main branch and the distal branch were minimally increased after deployment of this novel stent. The side branch was preserved, and the stresses on the side branch were lesser. At the confluence of the bifurcation on either side of the side branch origin the Von Mises stresses were marginally increased. However, the stresses at the bifurcation were significantly lesser than the stresses of the currently existing techniques used in the treatment of bifurcation lesions. Further, the tram area was studied parametrically to reduce the stresses. A firm lesion model with a stenosis of 80% was then created with a discrete lesion in side-branch and the main vessel. The stent was deployed in the main branch and the side branch was stented at the ostium. The stresses at the bifurcation and the main vessel was further reduced and the stent deployed well. Conclusions: There is a potential for a novel Tram-stent method in the treatment of coronary bifurcation lesions.
Bi-directional translational research with angiotensin-(1-7) uncovers placental growth factor as a therapeutic target
Authors: W. Petty, Antonius Miller, Thomas McCoy, Patricia Gallagher, E. Tallant, Frank Torti
Journal: Cancer Research (2008)

4968   Background: Angiotensin-(1-7) [Ang-(1-7)], is an endogenous peptide hormone that has anti-proliferative and anti-angiogenic activity in murine xenograft models. Placental growth factor (PlGF) is a potent angiogenic ligand that has an uncertain role in cancer angiogenesis. Blood vessel sarcomas have been characterized by high expression of PlGF and translocations involving this gene.  Methods: Ang-(1-7) was administered to patients by subcutaneous injection with dose escalation occuring in cohorts of 3 patients. Plasma levels of pro-angiogenic ligands were measured in patients with advanced solid tumors before Ang-(1-7) treatment as well as 1, 2, 3, 4, and 6 hours following treatment. Changes in PlGF expression over time were assessed by regression analysis stratified by patient. The effect of Ang-(1-7) on PlGF expression was also investigated in a murine A549 xenograft model. Athymic mice were injected with human A549 lung cancer cells and, once the tumors reached a size of 100 mm 3 , the animals were administered Ang-(1-7) (1000 µg/kg/day) or saline by subcutaneous injection. The mice were injected daily, for 5 days, followed by a 2 day rest period, and the injections were continued for 7 cycles. PlGF mRNA was quantified in the tumor tissue by reverse transcriptase, real-time polymerase chain reaction.  Results: Of the first five patients treated with Ang-(1-7), pre-treatment plasma levels of PlGF were found to be highest in a patient with a metastatic blood vessel sarcoma (hemangiopericytoma). Following Ang-(1-7) administration, the levels of PlGF in this patient decreased over time (p = 0.006). This patient experienced stable disease with cystic changes apparent in a liver metastasis after two cycles. PlGF levels were also reduced after Ang-(1-7) treatment in one additional patient (p = 0.005). In the preclinical study, treatment with Ang-(1-7) reduced levels of PlGF mRNA in murine A549 xenografts compared to saline treated controls (1.02 ± 0.07 relative gene expression versus 0.60 ± 0.04), suggesting transcriptional regulation of PlGF by the heptapeptide.  Conclusions: Ang-(1-7) is a first-in-class compound for the treatment of cancer that reduces plasma levels of placental growth factor in certain patients with advanced solid tumors.
James Kenechukwu Onwubalili
Authors: James Chidi Onwubalili
Journal: BMJ (2017)

James Kenechukwu Onwubalili (“JK”) fought in the Nigerian civil war in 1965 as a captain. He attended the University of Ibadan Medical School where he graduated in 1975, with a distinction as the best medical student. In 1985 he was awarded an MD for his thesis entitled “A Spectrum of Immunity in Tuberculosis,” …
HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas
Authors: Mianen Sun, Pan Tong, Wen Kong, Baijun Dong, Yiran Huang, In Young Park, Lijun Zhou, Xian-De Liu, Zhiyong Ding, Xuesong Zhang, Shanshan Bai, Peter German, Reid Powell, Quan Wang, Xuefei Tong, Nizar M. Tannir, Surena F. Matin, W. Kimryn Rathmell, Gregory N. Fuller, Ian E. McCutcheon, Cheryl L. Walker, Jing Wang, Eric Jonasch
Journal: Cancer Research (2017)

Chromophobe renal cell carcinoma (ChRCC) is characterized by major changes in chromosomal copy number (CN). No model is available to precisely elucidate the molecular drivers of this tumor type. HNF1B is a master regulator of gene expression. Here, we report that the transcription factor HNF1B is downregulated in the majority of ChRCC and that the magnitude of HNF1B loss is unique to ChRCC. We also observed a strong correlation between reduced HNF1B expression and aneuploidy in ChRCC patients. In murine embryonic fibroblasts or ACHN cells, HNF1B deficiency reduced expression of the spindle checkpoint proteins MAD2L1 and BUB1B, and the cell-cycle checkpoint proteins RB1 and p27. Furthermore, it altered the chromatin accessibility of Mad2l1, Bub1b, and Rb1 genes and triggered aneuploidy development. Analysis of The Cancer Genome Atlas database revealed TP53 mutations in 33% of ChRCC where HNF1B expression was repressed. In clinical specimens, combining HNF1B loss with TP53 mutation produced an association with poor patient prognosis. In cells, combining HNF1B loss and TP53 mutation increased cell proliferation and aneuploidy. Our results show how HNF1B loss leads to abnormal mitotic protein regulation and induction of aneuploidy. We propose that coordinate loss of HNF1B and TP53 may enhance cellular survival and confer an aggressive phenotype in ChRCC. Cancer Res; 77(19); 5313-26. ©2017 AACR.
AB0706 Ankylosing spondylitis patients with uveitis had better adalimumab retention rate: hur-bio real life results
Authors: B Armagan, A Sari, A Erden, L Kilic, DC Guven, T Pashayev, E Bilgin, C Simsek, EC Erdat, O Karadag, A Akdogan, S Apras Bilgen, S Kiraz, I Ertenli, U Kalyoncu
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Retention of biological drugs in inflammatory arthritis may be affected from different obvious and unknown factors. It can be related with patient characteritics or disease features. In ankylosing spondylitis (AS), retention rate of biological drugs may be related with extra-articular presentation of AS such as uveitis, as well. <h3>Objectives</h3> The objective of this study was to assess whether uveitis affected retention of adalimumab in AS patients in our single center biological cohort. <h3>Methods</h3> Hacettepe University Biological registry is single-center biological registry since 2005. HURBIO had 2165 spondyloarthritis patients of which 1190 patients had AS according to NY criteria. Until now, in 510 of 1190 patients have used adalimumab and 350 of 510 patients had available for uveitis. Patients were assessed for demographic characteristics, disease duration, HLA-B27, DMARD and biological usage, biological switch ratio. Baseline disease activity was assessed with BASDAI, BASFI VAS (pain, fatigue and patients global assessment), ESR and CRP. Patients were compared according to having uveitis or not. Retention rate of adalimumab assessed by Kaplan-Meier survival analysis. <h3>Results</h3> Total 350 (59.4% male) AS patients analyzed. Mean age was 43 (12), mean disease duration and symptom duration were 10.5 (7.8) and 14.8 (9.6) years, respectively. 52 patients (14.8%) had uveitis. Median adalimumab survival time according to having uveitis were 71.9 (95% CI 25.4–118.6) months vs 36.4 (95% CI 23.3–49.4) months (log-rank p=0.014) (figure). Patients with uveitis were more frequently male (18.2% vs 9.8%, p=0.03), HLA-B27 positive (75.0% vs 49.5%, p=0.022). Patients with uveitis had more frequently SpA family history, as well (23.1% vs 10.8%, p=0.003). Age (49 (11) vs 41 (11) years, p&lt;0.001), disease duration (14.4 (10.1) vs 9.8 (7.1) years, p&lt;0.001), and symptom duration (22 (12) vs 14 (8) years, p&lt;0.001) were higher in patients with uveitis. Baseline and last visit disease activities were similar regarding to uveitis. <h3>Conclusions</h3> Determination of possible risk factors for retention of TNFi drugs is an important clinical problem for routine practise. It is well known that adalimumab is one of the treatment option for uveitis whether uveitis related with SpA or not. Our biological cohort supported that AS patients with uveitis had better adalimumab survival. For routine practise, adalimumab could be considered for AS patients with uveitis. <h3>Disclosure of Interest</h3> None declared
抗血小板療法,アスピリン対チエノピリジン投与患者における心房細動の臨床転帰:伏見AFレジストリー
Authors: Masunaga Nobutoyo, Abe Mitsuru, Esato Masahiro, Chun Yeong‐Hwa, Tsuji Hikari, Wada Hiromichi, Hasegawa Koji, Ogawa Hisashi, Akao Masaharu
Journal: Circulation (2016)
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis
Authors: Lawrence F. Eichenfield, Robert S. Call, Douglass W. Forsha, Joseph Fowler, Adelaide A. Hebert, Mary Spellman, Linda F. Stein Gold, Merrie Van Syoc, Lee T. Zane, Eduardo Tschen
Journal: Journal of the American Academy of Dermatology (2017)

Long-term topical treatment is often required for atopic dermatitis (AD), a chronic inflammatory skin disease.To assess the long-term safety results from a multicenter, open-label, 48-week safety study (AD-303) of patients (N = 517) ≥2 years of age with mild to moderate AD who continued crisaborole treatment, a topical phosphodiesterase-4 inhibitor, after completing a 28-day phase 3 pivotal study (AD-301, AD-302).Global disease severity was assessed in patients every 4 weeks, and if assessed as mild or greater, a 28-day treatment period with crisaborole applied twice daily was initiated. Adverse events (AEs), including treatment-emergent AEs (TEAEs), and serious AEs were analyzed.During the pivotal studies and AD-303, 65% of patients reported ≥1 TEAE, most of which were mild (51.2%) or moderate (44.6%) and considered unrelated to treatment (93.1%). The frequency and severity of TEAEs were consistent. The most frequently reported treatment-related AEs (overall, 10.2%) were dermatitis atopic (3.1%), application-site pain (2.3%), and application-site infection (1.2%). Nine patients (1.7%) discontinued the long-term study because of TEAEs.Long-term efficacy was not analyzed.Crisaborole ointment had a low frequency of treatment-related AEs over 48 weeks of treatment of patients with AD.
Some Fundamental Aspects of Tumor Development Illustrated by Studies With Ultraviolet Radiation
Authors: Harold F. Blum
Journal: JNCI Journal of the National Cancer Institute (1943)

Journal Article Some Fundamental Aspects of Tumor Development Illustrated by Studies With Ultraviolet Radiation Get access Harold F. Blum Harold F. Blum senior pharmacologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 3, Issue 5, June 1943, Pages 569–581, https://doi.org/10.1093/jnci/3.5.569 Published: 01 June 1943
Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery
Authors: Neil K Taunk, Jung Hun Oh, Amita Shukla-Dave, Kathryn Beal, Behroze Vachha, Andrei Holodny, Vaios Hatzoglou
Journal: Neuro-Oncology (2017)

Imaging criteria to evaluate the response of brain metastases to stereotactic radiosurgery (SRS) in the early posttreatment period remains a crucial unmet need. The aim of this study is to correlate early (within 12 wk) posttreatment perfusion MRI changes with long-term outcomes after treatment of lung cancer brain metastases with SRS.Pre- and posttreatment perfusion MRI scans were obtained in patients treated with SRS for intact non-small cell lung cancer brain metastases. Time-dependent leakage (Ktrans), blood plasma volume (Vp), and extracellular extravascular volume (Ve) were calculated for each lesion. Patients were followed longitudinally with serial MRI until death, progression, or intervention (whole brain radiation or surgery).We included 53 lesions treated with SRS from 41 total patients. Median follow-up after treatment was 11 months. Actuarial local control at one year was 85%. Univariate analysis demonstrated a significant difference (P = 0.032) in posttreatment Ktrans SD between patients with progressive disease (mean = 0.0317) and without progressive disease (mean = 0.0219). A posttreatment Ktrans SD cutoff value of 0.017 was highly sensitive (89%) for predicting progressive disease and no progressive disease. Early posttreatment volume change was not associated with outcome (P = 0.941).Posttreatment Ktrans SD may be used as an early posttreatment imaging biomarker to help predict long-term response of lung cancer brain metastases to SRS. This can help identify patients who will ultimately fail SRS and allow for timelier adjustment in treatment approach. These data should be prospectively validated in larger patient cohorts and other histologies.
Dexamethasone Without Antibiotics for Sore Throat—Reply
Authors: Gail Nicola Hayward, Michael V. Moore, Carl Heneghan
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 33: Prostaglandin E2 Reduces Cardiac Contractility via EP3 Receptor
Authors: Xiaosong Gu, Jiang Xu, Xiao-Ping Yang, Edward Peterson, Pamela Harding
Journal: Circulation Research (2015)

Prostaglandin E2 (PGE2) EP receptors EP3 and EP4 are present in the heart and signal via decreased and increased cAMP production, respectively. Previously we reported that cardiomyocyte-specific EP4 KO mice develop a phenotype of dilated cardiomyopathy with reduced ejection fraction. We thus hypothesized that PGE2 decreases contractility via EP3. To test this hypothesis, the effects of PGE2 and the EP1/EP3 agonist sulprostone (sulp) were examined in the mouse langendorff preparation and in adult mouse cardiomyocytes (AVM) using the IonOptix cell contractility system. Isolated hearts of 18-20 wk old male C57Bl/6 mice were mounted and equilibrated for 10 min, then perfused with PGE2 (10 -6 mol/l) or sulp (10 -6 mol/l) for 30 min. Values at the end of equilibration were set to 100%. Compared to vehicle, PGE2 decreased +dp/dt (77.8±3% vs 96.7±3%, p&lt;0.01) and left ventricular developed pressure, LVDP (77.2±2% vs 96.8±3%, p&lt;0.001). Sulp decreased +dp/dt (75.9±2% vs 96.7±3%, p&lt;0.001), -dp/dt (72.2±1% vs 85.7±1%, p&lt;0.01) and LVDP (70.9±1% vs 96.8±3%, p&lt;0.001). The effects of both PGE2 and sulp were reversed by the EP3 antagonist, L789,106 (10 -6 mol/l). Myocyte contractility was evaluated on the IonOptix system with pacing at 1Hz. Treatment with PGE2 (10 -9 M) for 10 min reduced contractility as measured by peak height (3.69 ± 0.48% for vehicle vs 2.00 ± 0.22% for PGE2, p &lt; 0.05 ), departure velocity (-171.9 ± 22.9 um/sec for vehicle vs -106.3± 12.5 um/sec for PGE2, p &lt; 0.05) and return velocity (87.7 ± 16.3 um/sec for vehicle vs 36.7 ± 6.6 um/sec for PGE2, p &lt; 0.05) with similar effects noted for sulp. Sulp reduced change in peak height (4.79 ± 1.15% for vehicle vs 1.81 ± 0.37% for sulp, p &lt; 0.05), departure velocity (-169.1 ± 35.8 um/sec for vehicle vs -59.4 ± 10.3 um/sec for sulp, p &lt; 0.05) and return velocity (86.5 ± 23.8 um/sec for vehicle vs 16.9 ± 14.7 um/sec for sulp, p &lt; 0.05). We then examined the acute effects of PGE2 and sulp on expression of phosphorylated phospholamban (PLN) and SERCA using Western blot. Treatment of AVM for 15min with either PGE2 or sulp decreased expression of phosphorylated PLN corrected to total PLN, by 67% and 43%. SERCA2a expression was unaffected. In conclusion, PGE2 and sulp reduce contractility via the EP3 receptor through effects on PLN.
Role of MEK partner-1 in cancer stemness through MEK/ERK pathway in cancerous neural stem cells, expressing EGFRviii
Authors: Soo-Jung Kwon, Ok-Seon Kwon, Keun-Tae Kim, Young-Hyun Go, Si-in Yu, Byeong-ha Lee, Hiroyuki Miyoshi, Eunsel Oh, Seung-Ju Cho, Hyuk-Jin Cha
Journal: Molecular Cancer (2017)

Glioma stem cells (GSCs) are a major cause of the frequent relapse observed in glioma, due to their high drug resistance and their differentiation potential. Therefore, understanding the molecular mechanisms governing the 'cancer stemness' of GSCs will be particularly important for improving the prognosis of glioma patients.We previously established cancerous neural stem cells (CNSCs) from immortalized human neural stem cells (F3 cells), using the H-Ras oncogene. In this study, we utilized the EGFRviii mutation, which frequently occurs in brain cancers, to establish another CNSC line (F3.EGFRviii), and characterized its stemness under spheroid culture.The F3.EGFRviii cell line was highly tumorigenic in vitro and showed high ERK1/2 activity as well as expression of a variety of genes associated with cancer stemness, such as SOX2 and NANOG, under spheroid culture conditions. Through meta-analysis, PCR super-array, and subsequent biochemical assays, the induction of MEK partner-1 (MP1, encoded by the LAMTOR3 gene) was shown to play an important role in maintaining ERK1/2 activity during the acquisition of cancer stemness under spheroid culture conditions. High expression of this gene was also closely associated with poor prognosis in brain cancer.These data suggest that MP1 contributes to cancer stemness in EGFRviii-expressing glioma cells by driving ERK activity.
Oncogenic Human Polyomaviruses
Authors: Alan A. Schreier, Ph.D., Jack Gruber, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Oncogenic Human Polyomaviruses Get access Alan A. Schreier, Ph.D., Alan A. Schreier, Ph.D. Biological Carcinogenesis Branch, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, Bethesda, Maryland 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar Jack Gruber, Ph.D. Jack Gruber, Ph.D. Biological Carcinogenesis Branch, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, Bethesda, Maryland 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 76, Issue 6, June 1986, Pages 1255–1258, https://doi.org/10.1093/jnci/76.6.1255 Published: 01 June 1986